TW202330032A - 一種抗ｓｏｓｔ抗體醫藥組成物及其用途 - Google Patents

一種抗ｓｏｓｔ抗體醫藥組成物及其用途 Download PDF

Info

Publication number
TW202330032A
TW202330032A TW111145967A TW111145967A TW202330032A TW 202330032 A TW202330032 A TW 202330032A TW 111145967 A TW111145967 A TW 111145967A TW 111145967 A TW111145967 A TW 111145967A TW 202330032 A TW202330032 A TW 202330032A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
seq
antibody
concentration
sost
Prior art date
Application number
TW111145967A
Other languages
English (en)
Chinese (zh)
Inventor
單爽
田晨敏
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海恆瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海恆瑞醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202330032A publication Critical patent/TW202330032A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW111145967A 2021-11-30 2022-11-30 一種抗ｓｏｓｔ抗體醫藥組成物及其用途 TW202330032A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111462784.6 2021-11-30
CN202111462784 2021-11-30

Publications (1)

Publication Number Publication Date
TW202330032A true TW202330032A (zh) 2023-08-01

Family

ID=86611532

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111145967A TW202330032A (zh) 2021-11-30 2022-11-30 一種抗ｓｏｓｔ抗體醫藥組成物及其用途

Country Status (8)

Country Link
US (1) US20250011411A1 (enExample)
EP (1) EP4434517A4 (enExample)
JP (1) JP2024543931A (enExample)
CN (1) CN118175993A (enExample)
AU (1) AU2022401939A1 (enExample)
CA (1) CA3238868A1 (enExample)
TW (1) TW202330032A (enExample)
WO (1) WO2023098694A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
HK1200322A1 (en) * 2011-10-24 2015-08-07 Abbvie Inc. Immunobinders directed against sclerostin
SI3269735T1 (sl) 2015-03-13 2020-12-31 Jiangsu Hengrui Medicine Co. Ltd. Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN109952093B (zh) 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
EP4013786A1 (en) * 2019-08-12 2022-06-22 Amgen Inc. Anti-sclerostin antibody formulations

Also Published As

Publication number Publication date
AU2022401939A1 (en) 2024-05-30
CN118175993A (zh) 2024-06-11
WO2023098694A1 (zh) 2023-06-08
US20250011411A1 (en) 2025-01-09
EP4434517A1 (en) 2024-09-25
EP4434517A4 (en) 2025-06-25
JP2024543931A (ja) 2024-11-26
CA3238868A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
CN111315411B (zh) 高浓度抗c5抗体制剂
EP2844286B1 (en) Lyophilised and aqueous anti-cd40 antibody formulations
CN109952093B (zh) 一种sost抗体药物组合物及其用途
TW201927337A (zh) 一種ｌａｇ－３抗體醫藥組成物及其用途
CN110732023A (zh) 一种her2抗体药物组合物及其用途
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
JP2018531980A (ja) 抗ｄ因子抗体製剤
WO2020200099A1 (zh) 包含抗il-5抗体的药物组合物及其用途
WO2024109914A1 (zh) 一种包含特异性结合hgfr和egfr的双特异性抗体的药物组合物
TWI907576B (zh) 一種含抗結締組織生長因子抗體的醫藥組成物
TW202330032A (zh) 一種抗ｓｏｓｔ抗體醫藥組成物及其用途
BR112021010414A2 (pt) Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas
CN114786717B (zh) 稳定的水性抗-tfpi抗体制剂
CN115227813A (zh) 一种含抗Abeta抗体的药物组合物
HK40009387B (en) Sost antibody pharmaceutical composition and uses thereof
HK40009387A (en) Sost antibody pharmaceutical composition and uses thereof
CN118078988A (zh) 包含靶向il-17a的抗体药物组合物
TW202333789A (zh) 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途
TW202541841A (zh) 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
TW202529809A (zh) 一種抗tslp抗體的醫藥組成物及其用途
CN116803420A (zh) 靶向PD-1和TGFβ的双功能蛋白药物组合物及其用途
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂
HK40023281A (en) Lyophilised and aqueous anti-cd40 antibody formulations
HK1202050B (en) Lyophilised and aqueous anti-cd40 antibody formulations